Clinical Trials
44 trialsPembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
M.D. Anderson Cancer Center
Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy
Masonic Cancer Center, University of Minnesota
Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies
H. Lee Moffitt Cancer Center and Research Institute
A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)
Case Comprehensive Cancer Center
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
City of Hope Medical Center
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
Masonic Cancer Center, University of Minnesota
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
Roswell Park Cancer Institute
Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT
Masonic Cancer Center, University of Minnesota
CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma
Wake Forest University Health Sciences
Daratumumab Plus Gemcitabine, Dexamethasone, Cisplatin in pt R/R CD38+ PTCL-NOS, AITL and TFH
Fondazione Italiana Linfomi - ETS
PRIMO
SecuraBio
Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies
M.D. Anderson Cancer Center
Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms
BeiGene
CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma
Emergent BioSolutions
Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation
Stanford University
Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma
City of Hope Medical Center
Ruxolitinib Phosphate to Treat Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma After Stem Cell Transplant
University of Nebraska
CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma
Dana-Farber Cancer Institute
SOLAR
miRagen Therapeutics, Inc.
273
Brown University
Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas
National Institutes of Health Clinical Center (CC)
CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma
Stanford University
A Study for Patients With Non-Hodgkin's Lymphomas
Eli Lilly and Company
Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Mayo Clinic
Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma
National Cancer Institute (NCI)
Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma
Fred Hutchinson Cancer Center
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
Celgene
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
Fred Hutchinson Cancer Center
PROPEL
Acrotech Biopharma Inc.
EXPECT
Celgene
Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia
Fred Hutchinson Cancer Center
FIL_GEMRO
Fondazione Italiana Linfomi - ETS
Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma
Takeda
Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas
University of Michigan Rogel Cancer Center
UCN-01 (7-Hydroxystaurosporine) to Treat Relapsed T-Cell Lymphomas
National Institutes of Health Clinical Center (CC)
Tandem Auto-Allo Transplant for Lymphoma
Massachusetts General Hospital
Gleevec in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma
Dana-Farber Cancer Institute
A Phase II Study of Doxycycline in Relapsed NHL
University of Rochester
A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma
Seagen Inc.
Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma
Rigel Pharmaceuticals
Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma
National Cancer Institute (NCI)
Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma
M.D. Anderson Cancer Center
Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma
M.D. Anderson Cancer Center